Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The study's hypothesis is that using Nivolumab as early switch maintenance, after 4‐6 cycles of standard first‐line chemotherapy, might improve survival in patients with advanced stage squamous NSCLC.
Epistemonikos ID: 810e381c328bb63416e034c53f678ce910a8272d
First added on: May 21, 2024